Researchers found that antibodies from vaccinated individuals can effectively target the measles virus. In a recent study, scientists analyzed blood samples from 20 people who received the measles, mumps, and rubella (MMR) vaccine and identified four antibodies that can attach to the virus and prevent it from infecting cells. This discovery is significant because, despite the measles vaccine being available for over 60 years, the specific antibodies that protect against the virus were not well understood until now.

This research matters for your health as it opens the door to new treatments for measles, especially for those who cannot receive the vaccine, such as infants under 12 months and immunocompromised individuals. With over 10 million measles cases reported globally each year, effective treatments could help protect vulnerable populations, including children with cancer. The identified antibodies could potentially be developed into long-acting preventive treatments, similar to those already used for other viruses.

The study is in the early stages, having tested the antibodies in cotton rats, which are not perfect models for human disease progression. While the findings are promising, more research is needed to confirm their effectiveness in humans. The researchers plan to advance these antibodies into preclinical testing and clinical trials, which could lead to new therapies for measles in the future.

If you’re concerned about measles, staying informed about vaccination and emerging treatments is essential. While the MMR vaccine remains the best protection, these new antibody treatments could provide additional options for those at risk.

Source: fiercebiotech.com